Patient characteristics
| Characteristic . | No. of patients . | Mean false positive rate* . |
|---|---|---|
| Patients | 25 | — |
| Girls | 8 | — |
| Boys | 17 | — |
| Pre-HSCT therapy | 21 | — |
| Chemotherapy only | 10 | — |
| Splenectomy only | 3 | — |
| Chemotherapy and splenectomy | 8 | — |
| Remission following first HSCT | 11 | — |
| Transplantation-related mortality | 2 | — |
| Relapse following first HSCT | 12 | — |
| Second HSCT | 4 | — |
| Median duration of post-HSCT follow-up | 1.8 y | — |
| Mutation | ||
| PTPN11 g226G>A | 13 | 0.0000 |
| PTPN11 214G>A | 3 | 0.0059 |
| PTPN11 227A>G | 2 | 0.0712 |
| NRAS 38G>A | 2 | 0.0203 |
| KRAS 38G>A | 2 | 0.0237 |
| PTPN11 1508G>C | 1 | 0.0162 |
| NRAS 37G>C | 1 | 0.0000 |
| KRAS 35G>A | 1 | 0.3449 |
| Characteristic . | No. of patients . | Mean false positive rate* . |
|---|---|---|
| Patients | 25 | — |
| Girls | 8 | — |
| Boys | 17 | — |
| Pre-HSCT therapy | 21 | — |
| Chemotherapy only | 10 | — |
| Splenectomy only | 3 | — |
| Chemotherapy and splenectomy | 8 | — |
| Remission following first HSCT | 11 | — |
| Transplantation-related mortality | 2 | — |
| Relapse following first HSCT | 12 | — |
| Second HSCT | 4 | — |
| Median duration of post-HSCT follow-up | 1.8 y | — |
| Mutation | ||
| PTPN11 g226G>A | 13 | 0.0000 |
| PTPN11 214G>A | 3 | 0.0059 |
| PTPN11 227A>G | 2 | 0.0712 |
| NRAS 38G>A | 2 | 0.0203 |
| KRAS 38G>A | 2 | 0.0237 |
| PTPN11 1508G>C | 1 | 0.0162 |
| NRAS 37G>C | 1 | 0.0000 |
| KRAS 35G>A | 1 | 0.3449 |
— indicates not applicable.
See Figure S1 for graphic depiction of false positive rates.